Objective: Epigenetic modulation of gene expression by DNA promoter methylation may contribute to acquired resistance to chemotherapy in cancer cells. Decitabine (5-aza-2'-deoxycytidine), a demethylating agent, may act synergistically with standard chemotherapy regimens to activate epigenetically silenced genes. In the present in vitro study, it was investigated the effect of gene methylation level after treatment with decitabine and combination of decitabine with anthracycline-based therapeutics (5-fluorouracil plus epirubicine plus cyclophosphamide; FEC) on breast cancer cells (MCF-7 and MDA-MB-231). Methods: The effect of decitabine and its combination with FEC on different genes methylation level has been tested in MDA-MB-231 and MCF-7 human breast cancer cell lines. The effect of decitabine on the cell viability was assayed by MTT assay. Methylight real-time PCR and methylation specific PCR were carried out to determine the methylation status of certain genes: DAPK, TMS1, MGMT and the global methylation marker LINE-1. Results: The LINE-1 methylation status significantly decreased in both cell lines after treatment with the combination of decitabine with FEC. In MDA-MB-231 cells, methylation of the TMS1 and the MGMT gene promoter was significantly reduced by FEC plus decitabine while no effect was observed in MCF-7 cells. Conclusion: Anthracycline-based therapy regimens in combination with demethylating agents such as decitabine may affect chemotherapy outcome by modulation of apoptosisrelevant genes by methylation. More importantly, this modulation seems to be dependent on the cell type. Key Words: DNA methylation, breast cancer, apoptosis, decitabine, FEC Conflict of Interest: The authors do not have any conflict of interest.
Introduction
Breast cancer is recognized as the most common malignancy among women. Substantial advances in therapy and diagnosis have enhanced the survival rate of breast cancer patients [1] . Chemotherapy plays a major role in the treatment of patients with cancer, particularly breast cancer. Adjuvant treatment of high risk breast cancer patients with anthracycline containing regimens (5-fluorouracil plus epirubicine plus cyclophosphamide; FEC) has been proven to be highly effective for treating patients with advanced breast cancer [2] . Research programs led to the identification of a variety of therapy option for breast cancer. Epigenetic mechanisms such as DNA methylation are now recognized to play an important role in cancer. Altering the DNA methylation machinery is a potentially powerful approach to cancer therapy [3] .
DNA methylation is a covalent modification of the DNA formed by addition of a methyl group at the 5' carbon residue of cytosine in so-called CpG dinucleotide repeats [4] . DNA methylation, once established, acts as a dominant factor in down-regulation of gene expression. Aberrant DNA methylation plays also an important role in carcinogenesis and tumor apoptosis [5] . DNA hypermethylation occurs in many genes in breast carcinogenesis [6] . Gene-specific methylation has also been suggested as a useful tool for prediction of prognosis or response to treatment in early and advanced breast cancer patients [7, 8] . Since epigenetic silencing of genes is known to be associated with breast cancer progression [5, 9] . Recent studies showed that promoter methylation of genes used as a biomarker for predicting prognosis in breast cancer [10] [11] [12] .
Several preclinical cell line and animal models have shown a physiological impact of the DNA methyltransferase inhibitor decitabine (5-aza-2'-deoxycytidine, DAC) as a demethylating agent on gene expression and tumor development [13] [14] [15] . Decitabine reverses the hypermethylation status of CpG repeats in gene promoters inducing transcriptional reactivation of epigenetically silenced genes, ultimately leading to restoration of apoptosis and inhibition of tumor growth [16] [17] [18] . In fact, re-expression of silenced tumor suppressor genes with demethylating drugs will effect inhibition of cancer cell growth in vitro and in vivo [19, 20] .
In the present report, we employed a human estrogen receptor negative, highly invasive breast cancer cell line (MDA-MB-231) and an estrogen receptor positive, non-invasive breast cancer cell line (MCF-7) to determine the changes in DNA methylation of DAPK (Death-Associated Protein Kinase), TMS1 (Target of Methylation-Induced Silencing 1; apoptosis), MGMT (O6-Methylguanine-DNA Methyltransferase; DNA repair) LINE-1(Long-Interspersed Repetitive Elements; global methylation marker) genes as a response to the combined chemotherapies with decitabine.
Materials and Methods

Chemicals, Anticancer Drugs and Cell Culture
Decitabine was obtained from Sigma (St. Louis, MO). 5-Fluorouracil (5-FU; EBEWE Pharma, Austria), 4-HC (4-hydroperoxycyclophosphamide, the active metabolite of cyclophosphamide; NIOMECH, Germany), and epirubicine (EBEWE Pharma, Austria) were obtained from the Pharmacy of the Uludag University Hospital, representing standard drug regimens normally used for breast cancer treatment. Stock concentrations of each drug were prepared either in PBS (Phosphate Buffer Saline) or in the dilution buffer provided by the drug company. Working dilutions of the drugs were prepared from stock solutions by diluting them in the appropriate culture medium. For each drug, four different concentrations were used and defined as test drug concentrations (TDC). TDC were determined by pharmacokinetic/clinical information and clinical evaluation data [21] . 100% TDC was defined as mean plasma drug concentration assayed after standard FEC dose administration in cancer patients [22] . Hereby, 100% TDC values (in µg/mL) were defined as follows: 5-FU: 22.50, epirubicine: 0.50, 4-HC: 3.0. Drug concentrations used for in vitro experiments were 200, 100, 50, and 25% of TDC. Breast cancer cell lines MCF-7 and MDA-MB-231 were cultured in RPMI 1640 supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine, and 10% fetal calf serum (Invitrogen, Paisley, UK) at 37 °C in a humidified atmosphere containing 5% CO 2 .
MTT Viability Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) cell viability assay was performed as previously described [23] . MCF-7 and MDA-MB-231 cells were seeded per well of a 96-well plate in 200 ml culture medium in triplicates at a density of 5x10 3 cells. After overnight incubation, media were replaced by fresh ones with or without the decitabine. Cells were treated for 24 and 48 h with 1.25-10 µM decitabine. MTT was supplied as a stock solution (5 mg/ml PBS, pH 7.2) and sterile-filtered. At the end of the treatment period, 25 μl of MTT solution was added to each well and then, after another 4 h at 37 ºC, 100 μl of solubilizing buffer (10% SDS dissolved in 0.01 N HCl) was added to each well. After overnight incubation, the absorbance was determined by an ELISA plate reader (FLASH Scan S12, Analytik Jena, Germany) at 570 nm as a read-out for cell viability. Cell viability of treated cells was calculated in reference to the untreated control cells using the formula: Viability (%) = [100 x (Sample Abs)/(Control Abs)].
DNA Extraction and Bisulfite Modification
Total cellular DNA was extracted by use of the Genomic DNA Puregene Purification Kit (Qiagen, Hilden, Germany); sodium bisulfite conversion of (un)methylated cytosine was performed using the Epitect Bisulfit kit 
Analysis of Gene Promoter Methylation Status by Methylight Real-time PCR Assays
Bisulfite-converted DNA was analyzed in duplicates by the MethyLight technique as described previously [24] employing the ABI PRISM7700 Sequence Detection System instrument and software (Applied Biosystems, Inc., Foster City, USA). Methylation-specific real-time PCR for the marker genes LINE-1, DAPK, TMS1 and MGMT were performed in a final volume of 20 µL including 10 µl 2x Quantitect Probe mastermix (Qiagen), 2 µL bisulfite-treated DNA, and assay-defined primer and probe concentrations (Table 1 ). For normalization of input of bisulfite-converted DNA, an Alu1 reference system was used, containing a DNA-methylation statusindependent consensus sequence of the most common Alu1 repeat families [25] . The experiment included a no-template control and a positive control with known DNA-methylation status. SssI-treated human chromosomal DNA (Qiagen) was used as a reference of fully methylated cytosine. Primer and probes were purchased from Metabion (Martinsried, Germany), Applied Biosystems (Foster City, USA), or Microsynth (Lustenau, Austria).
Analysis of Gene Promoter Methylation Status by Methylation-specific PCR (MSP) analysis
Aberrant promoter methylation of TMS1 and DAPK gene was determined by the method of methylation specific PCR (MSP), as reported by Herman et al. [29] . MSP distinguishes unmethylated alleles of a given gene on the basis of DNA sequence alterations after bisulfite treatment of DNA, which converts unmethylated but not methylated cytosines to uracils. Subsequent PCR using primers specific to sequences corresponding to either methylated or unmethylated DNA sequences was then performed. PCR was performed using CpG WIZ TMS1/ASC and DAP-kinase Amplification Kits (Chemicon International, Canada, USA). Primer set U will anneal to unmethylated DNA that has undergone a chemical modification.
Primer set M will anneal to methylated DNA that has undergone a chemical modification. TThe unmethylated or methylated sequence of TMS1 and DAPK are shown in Table 2 . PCR conditions of TMS1 and DAPK promoters: 95ºC for 5 min, 40 cycles of 95ºC for 45 s, annealing for 56ºC 45 s and a final extension 72ºC for 60 s. PCR products was mixed with 1.5 μl of loading dye and then run on 2 % agarose gel. Electrophoresis was carried out at 75 V at ambient temperature. The bands on the gels were visualized by ethidium bromide staining. 
Statistical Analyses
All statistical analyses were performed using the SPSS 20.0
Results
Effect of Decitabine on cell viability of MCF-7 and MDA-MB 231 cells
The effect of decitabine (1.25-10 µM) was assessed by the MTT viability assay in MCF-7 and MDA-MB-231 breast cancer cells for 24 and 48h. Decitabine resulted in decrease in the cell viability (about 20% percent) at 10 µM after the treatment for 48 h in both cell types (Figure 1).
DNA-Methylation Status of Genes after Anthracycline-Based Therapy and Decitabine
We examined the effects of 100% TDC FEC, 10 µM, decitabine and their combination on DNA methylation status of certain cancer-related genes: DAPK, TMS1, MGMT and LINE-1 in the MDA-MB-231 and MCF-7 breast cancer cell lines by Methylight Realtime PCR Assay. LINE-1, as a marker for genome-wide methylation status, displays an elevated overall DNA methylation status for untreated MCF-7 cells when compared to MDA-MB-231 cells (60.9 vs 49.7% promoter methylated reference (PMR). The LINE-1 methylation status significantly decreased in both cell lines after treatment with combined FEC/decitabine drug treatment (p<0.05) ( Figure  2) . When FEC or decitabine are used as a single drug regimens, they impacted the overall methylation status of LINE-1 in MDA-MB-231 cells slightly, only except for treatment of MCF-7 cells with decitabine which led to significant reduction of the overall LINE-1 methylation status (Figure 2 ). DAPK promoter methylation was different in the MCF-7 and MDA-MB-231 cell lines, displaying a high methylation rate in the MCF-7 cell line but a low one in the MDA-MB-231 cells. In the MCF-7 cell line, the methylation rate of the DAPK promoter was significantly decreased by treatment with FEC, decitabine, or combination thereof. Likewise, in the MDA-MB-231 cells, the low DNA methylation status of the DAPK gene promoter was not significantly affected by the single drugs or combinations thereof (Figure 3) . Different from the above gene promoter DNA methylation status, the TMS1 and MGMT promoters were completely unmethylated in the MCF-7 cells. In MDA-MB-231 cells, methylation of the TMS1 gene promoter was significantly reduced by decitabine, FEC, or combination thereof. Even though that the MGMT promoter showed low methylation levels only in MDA-MB-231 cells, treatment with decitabine alone or in combination with FEC led to further reduction of the methylation signal ( Figure 4 ).
Analysis of TMS1 and DAPK gene promoter methylation by MSP
The analysis of the methylation status of TMS1 and DAPK apoptosis related genes in MCF-7 and MDA-MB-231 breast cancers was carried out by MSP analysis.
The results of representative MSP analyses are shown in Figure 5 . MCF-7 and MDA-MB-231 cells exhibit partial methylation of analyzed genes. In both cells, the TMS1 gene promoter was demethylated after FEC, DAC and combination (FEC+DAC) treatment. The methylation of DAPK promoter was decrease after treatment of DAC and FEC plus decitabine in both cells.
Discussion
Epigenetic alterations associated with human breast carcinogenesis including hypermethylation of tumor suppressor genes [9] which is also important to predict the risk of developing breast cancer [32, 33] . DNA methylation is catalyzed by DNA methyltransferases and inhibition of this mechanism is supposed to be beneficial in the treatment of this malignant disease [34] . Accordingly, DNA methyltransferase inhibitors such as decitabine, which lead to cytosine demethylation, activate epigenetically silenced genes [35] [36] [37] . This modification in genes by the effects of decitabine makes it a promising agent for used in cancer chemotherapy. The use of decitabine in combination with other polychemotherapy regimens may lead to even more effective therapy in breast cancer.
In the present study, we investigated methylation status of genes: DAPK, TMS1 (apoptosis-inducers), MGMT (DNA repair), and the global methylation marker LINE- 1 using DNA-methylation specific real-time PCR after treatment of decitabine plus FEC chemotherapy regime. In this study, we also examined the effects of decitabine on viability of the breast cancer cell lines MDA-MB-231 and MCF-7. Decitabine lead to decrease of cell viability at 20% percent (10 µM for 48) in both cells. In our previous study, we show that the treatment of MCF-7 and MDA-MB-231 cells with FEC significantly reduced cell viability in a dose-dependent manner. However, the combination of the different doses of FEC with 10 µM decitabine did not impair cell viability levels any further [38] .
The methylation level of LINE-1 (long-interspersed) repetitive elements was assessed by MethyLight assay which estimates total genomic DNA methylation [39] . Several clinical studies associated the DNA-methylation status of repetitive sequences like LINE-1 or Sat2 with clinical prognosis in different cancer types [40] [41] [42] . We demonstrated that the LINE-1 methylation status is higher in MCF-7 cells compared to MDA-MB-231 and that incubation of the cell lines with decitabine plus FEC resulted in significant reduction of the methylation status. Activation of general DNA repair pathways are involved in acquired resistance of cancer cells to chemotherapy and the MGMT (O6-methylguanine-DNA methyltransferase) gene, which is involved in the repair of alkylated DNA lesions [43, 44] . Promoter methylation of MGMT genes associated with loss of MGMT expression and diminished DNA-repair activity [45] . Recent studies suggested that the MDA-MB-231 cell line exerts MGMT silencing by promoter hypermethylation [46, 47] . In our hands, in MDA-MB-231 cells, the MGMT promoter showed only low methylation levels, still, treatment with decitabine alone or in combination with FEC led to further reduction of the methylation signal. In a previously study showed that partial demethylation of MGMT gene prompoter when paclitaxel, adriamycin and 5-fluorouracil combined with decitabine [48] . DAPK and TMS1 are supposed to play a pivotal role in the regulation of apoptosis, inflammatory signaling pathways, and immune response pathways [49] [50] [51] , which may be implicated in cancer progression [52, 53] . In our study, we found high promoter methylation levels of DAPK in the MCF-7 cell line and low methylation ratio in MDA-MB-231 cell line. On the opposite, the TMS1 promoter was hypermethylated in MDA-MB-231, which is consistent with reported studies [54] [55] [56] . Correlating results were also reported for DAPK and TMS1 mRNA and protein expression levels in various breast cancer cell lines [54, 57] . We found that in cells treated with decitabine, FEC, and the combination regimens, DAPK as well as TMS1 were significantly demethylated in the respective cell lines in a synergistic fashion. In addition, our previously data demonstrate that decitabine plus FEC treatments increased apoptosis than decitabine or FEC treatment alone in MCF-7 cells [38] , which may be a result of reactivation of gene expression by promoter demethylation.
Conclusions
In conclusion, these treatments lead to reduction of the methylation status of promoters of the TMS1 and DAPK genes. Furthermore epigenetic effects were also observed for FEC only regimens, which may be related to a kind of epigenetic adaption or selection process in the treated tumor cell population. We concluded that the therapy of FEC plus decitabine, even FEC alone, may affect therapy outcome by upregulation of apoptosis-relevant genes via hypomethylation.
